Last reviewed · How we verify
NCT02117219
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
Phase 1 trial testing MEDI4736 Evaluate MEDI4736 in MDS in Myelodysplastic Syndrome in 67 participants. Completed in 30 April 2019.
30 April 2019
Quick facts
| Lead sponsor | MedImmune LLC |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 67 |
| Start date | 20 May 2014 |
| Primary completion | 30 April 2019 |
| Estimated completion | 30 April 2019 |
| Sites | 21 locations across France, United Kingdom, United States, Germany |
Drugs / interventions tested
- MEDI4736 Evaluate MEDI4736 in MDS — full drug profile →
- VIDAZA (azacitidine) — full drug profile →
- tremelimumab (TREMELIMUMAB) — full drug profile →
Conditions studied
- Myelodysplastic Syndrome — all drugs for Myelodysplastic Syndrome →
Sponsor
MedImmune LLC — full company profile →
Who can join
Adults 18 to 99, any sex, with Myelodysplastic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with myelodysplastic syndrome after treatment with hypomethylating agents
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immune checkpoint therapy in liver cancer.
Xu F, Jin T, Zhu Y, Dai C. · · 2018 · cited 299× · PMID 29843754 · DOI 10.1186/s13046-018-0777-4 -
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
Yang J, Xu J, Wang W, Zhang B, et al · · 2023 · cited 251× · PMID 37217462 · DOI 10.1038/s41392-023-01480-x -
Combining epigenetic and immune therapy to overcome cancer resistance.
Gomez S, Tabernacki T, Kobyra J, Roberts P, et al · · 2020 · cited 130× · PMID 31877341 · DOI 10.1016/j.semcancer.2019.12.019 -
Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.
Lamble AJ, Lind EF. · · 2018 · cited 95× · PMID 29951373 · DOI 10.3389/fonc.2018.00213 -
Checkpoint inhibitors in hematological malignancies.
Ok CY, Young KH. · · 2017 · cited 93× · PMID 28482851 · DOI 10.1186/s13045-017-0474-3 -
The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P, Kantarjian H, Garcia-Manero G, Allison J, et al · · 2018 · cited 82× · PMID 28679300 · DOI 10.1080/10428194.2017.1344905 -
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Buqué A, Bloy N, Aranda F, Castoldi F, et al · · 2015 · cited 79× · PMID 26137403 · DOI 10.1080/2162402x.2015.1008814 -
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.
Wolff F, Leisch M, Greil R, Risch A, et al · · 2017 · cited 68× · PMID 28359286 · DOI 10.1186/s12964-017-0168-z
Verify or expand the search:
- PubMed search for NCT02117219
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myelodysplastic Syndrome
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT07422480 — A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myel · Phase 3 · recruiting
- NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting
- NCT06781099 — Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis · NA · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
Other MedImmune LLC trials
Trials by the same sponsor.
- NCT04145193 — Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC · Phase 2 · withdrawn
- NCT04522323 — A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma · Phase 1 · active not recruiting
- NCT03903718 — Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza · Phase 2 · withdrawn
- NCT04261075 — IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. · Phase 1 · completed
- NCT03889275 — A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02117219 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MedImmune LLC
- Last refreshed: 10 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02117219.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing